Cna Financial Corp Allovir, Inc. Transaction History

Cna Financial Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$16.97 - $25.06 $227,482 - $335,929	-13,405 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$19.44 - $25.06 $33,048 - $42,602	1,700 Added 14.52%	13,405 $265,000
Q1 2021 May 14, 2021	BUY	$20.81 - $45.5 $8,740 - $19,110	420 Added 3.72%	11,705 $274,000
Q4 2020 Feb 12, 2021	BUY	$23.94 - $46.81 $12,927 - $25,277	540 Added 5.03%	11,285 $434,000
Q3 2020 Nov 12, 2020	BUY	$21.05 - $42.7 $226,182 - $458,811	10,745 New	10,745 $295,000

21.1M

41K

100

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $913M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Cna Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Cna Financial Corp with notifications on news.